Table II.

Region analyses

	Area (mm2)	COGx	COGy	COGz	N vs. C	N vs. SD	N vs. SF	C vs. SD	C vs. SF	SD vs. SF
LH ROI
BA3, fingers	126	−48	−19	35	0.8231	0.9695	0.8308	0.8441	0.9932	0.8514
BA1, fingers	143	−51	−21	43	0.8041	0.8972	0.5016	0.6858	0.5848	0.4076
OP1	521	−54	−27	19	0.0030*	0.6862	0.1756	0.0142	<0.0001	0.0947
OP3	36	−39	−14	17	0.0215	0.8713	0.7415	0.0083	0.0338	0.5943
OP4	229	−57	−12	14	0.1141	0.5835	0.3824	0.2873	0.4453	0.7458
BA 40	949	−55	−52	26	0.0046	0.5534	0.6578	0.0229	0.0042	0.8091
BA 22	406	−54	−42	3	0.0129	0.0165	0.0228	0.9597	0.8634	0.8332
BA 7, anterior	1676	−44	−52	42	0.2785	0.0051	0.0457	0.0652	0.3839	0.2672
BA 7, posterior	1892	−26	−63	48	0.0044	0.0729	0.0845	<0.0001	<0.0001	0.8149
BA 4, fingers‐hand	1208	−48	−10	40	0.0858	0.5456	0.6459	0.0113	0.0133	0.8581
PMv	1675	−43	−1	36	0.1957	0.0454	0.1972	0.0032	0.0152	0.3815
PMd	275	−24	−9	57	0.6537	0.1189	0.0470	0.0802	0.0354	0.7138
FEF	246	−30	−12	51	0.0858	0.0773	0.3233	0.0009	0.0050	0.3405
Pre‐SMA	695	−8	12	45	0.2646	0.1127	0.9736	0.5849	0.3129	0.1416
SMA	608	−8	−7	56	0.5965	0.2769	0.3825	0.1455	0.1961	0.7597
BA 44, 46	1216	−39	22	35	0.2175	0.0782	0.1985	0.5669	0.9483	0.5007
Frontal operculum	405	‐34	8	10	0.1640	0.6788	0.5382	0.3153	0.3014	0.9099
RH ROI
OP1	398	49	‐27	25	0.0033	0.2300	0.7288	0.0294	0.0010	0.1410
OP4	398	54	‐11	17	0.0046	0.4560	0.6780	0.0255	0.0105	0.7268
BA 40	1194	54	‐37	37	0.0002	0.5943	0.8743	0.0034	0.0011	0.7372
BA 22	877	50	‐37	5	0.0005	0.0435	0.0793	0.0952	0.0467	0.7522
BA 7, anterior	1278	40	‐47	45	0.1612	0.0319	0.0335	0.3713	0.4054	0.9343
BA 7, posterior	2151	25	‐61	50	0.0281	0.0593	0.0984	0.0003	0.0004	0.7256
PMv	2033	35	‐2	46	0.6812	0.0818	0.2127	0.1898	0.4192	0.5823
Pre‐SMA	598	6	12	47	0.1937	0.1248	0.3680	0.7063	0.6795	0.4522
SMA	827	5	‐8	54	0.361	0.3282	0.7858	0.9648	0.5029	0.4655
BA 44	1162	45	12	24	0.0068	0.0453	0.1091	0.6889	0.2980	0.5886
BA 46	1303	38	30	30	0.0810	0.0924	0.2499	0.9796	0.4884	0.5152
Frontal operculum	348	31	17	8	0.1494	0.6203	0.7568	0.3937	0.0880	0.4460

^*Significance corrected for multiple comparisons based on six tests per ROI (shaded cells: ≤0.008).